Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.72 |
| ▸ | JAK2 | O60674 | 13/20 | 0.72 |
| ▸ | JAK1 | P23458 | 13/20 | 0.72 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15755880 | 0.94 | JAK3 (0.77) | JAK3JAK2JAK1EGLN1MAP4K4 | |
| SCHEMBL1370153 | 0.87 | JAK3 (0.78) | JAK3JAK2JAK1EGLN1GRM5 | |
| Ethylamine SCHEMBL1372020 | 0.85 | JAK3 (0.58) | JAK3JAK2JAK1EGLN1MAP4K4 | |
| SCHEMBL1369140 | 0.85 | JAK3 (0.75) | JAK3JAK2JAK1EGLN1GRM5 | |
| SCHEMBL1369138 | 0.84 | JAK3 (1.00) | JAK3JAK2JAK1SYK | |
| SCHEMBL1372266 | 0.83 | JAK3 (0.75) | JAK3JAK2JAK1EGLN1MAP4K4 | |
| SCHEMBL14655458 | 0.79 | JAK3 (0.74) | JAK3JAK2JAK1 | |
| SCHEMBL15755322 | 0.79 | JAK3 (0.59) | JAK3JAK2JAK1EGLN1MAP4K4 | |
| SCHEMBL1696902 | 0.76 | JAK3 (0.56) | JAK3JAK2JAK1PTGER4 | |
| SCHEMBL1368524 | 0.75 | JAK3 (0.76) | JAK3JAK2JAK1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.